Optellum
- hard tech
- biotechnology
- horizon europe
- woman founder
- risk management
- core ai
- spinout
- ai applications
- eit ecosystem
- oncology
- eit health
- patient care
- drug development
- techbio
- tech for hospitals & clinics
- eit supernovas
- tech for medical professionals
- health it
- physician support tools
- clinical decision support
- headstart (eit health)
- medical diagnostics
- medical imaging
- virtual assistant
- ai for imaging
- european health catapult (eit health)
- bia techbio uk
- headstart 2016 (eit health)
- pulmonary
- innovation projects (eit health)
- lungs
- european health catapult 2016 (eit health)
- innovation projects 2017 (eit health)
Financials
Estimates*
USD | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Revenues | 2.1m | 2.4m | 3.0m | 3.9m | 4.5m |
% growth | - | 14 % | 25 % | 30 % | 15 % |
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
€50.0k | Grant | ||
N/A | Spinout | ||
€50.0k | Grant | ||
N/A | Grant | ||
€50.0k | Grant | ||
* | £1.0m | Early VC | |
N/A | Support Program | ||
* | $14.0m | Series A | |
Total Funding | AUD23.9m |
Related Content
Recent News about Optellum
EditOptellum is a pioneering health technology startup focused on revolutionizing the early diagnosis and treatment of lung cancer. The company leverages advanced Artificial Intelligence (AI) and Machine Learning (ML) to develop decision support software that aids clinicians in identifying and managing lung cancer at its earliest stages. This innovative approach aims to improve patient outcomes by enabling earlier and more accurate diagnoses, which can significantly reduce waiting times for patients.
Optellum primarily serves healthcare providers, including top hospitals and physicians across Europe and the United States. The company collaborates closely with leading medical experts and institutions, including the Lung Cancer Initiative at Johnson & Johnson, to ensure its solutions are at the forefront of medical innovation.
Operating in the healthcare technology market, Optellum's business model revolves around the development and commercialization of its AI-based software. The company generates revenue by licensing its software to hospitals and medical practices, providing them with a powerful tool to enhance their diagnostic capabilities. This model not only supports the company's growth but also drives significant improvements in patient care.
Optellum's AI software has been validated through multi-center studies in Europe, demonstrating its ability to differentiate between benign and malignant lung nodules. This validation underscores the software's potential to transform lung cancer diagnosis and treatment, making it a valuable asset for healthcare providers aiming to improve patient outcomes.
In summary, Optellum is a cutting-edge health tech company that combines AI and ML to create diagnostic tools for early lung cancer detection. By partnering with top medical institutions and experts, the company aims to enhance the accuracy and efficiency of lung cancer diagnosis, ultimately improving patient care and reducing healthcare costs.
Keywords: AI, lung cancer, early diagnosis, healthcare, machine learning, medical software, patient care, hospitals, clinical experts, innovation.